Emergency Medicine Cardiac Research and Education Group




ACTION Registry
ACTION Registry®–GWTG™ is a national, risk-adjusted, outcomes-based quality improvement program that helps participating facilities measure and improve care for high-risk ACS patients with STEMI and NSTEMI. The result of the collaboration between the two leading national coronary artery disease registries, the NCDR® ACTION Registry® and the American Heart Association (AHA) Get With The GuidelinesSM-CAD Registry, ACTION Registry–GWTG will be the largest, most comprehensive national cardiovascular patient database ever developed by the medical profession.

Combining the strengths of the two programs, ACTION Registry–GWTG will collect a comprehensive set of data elements that provide healthcare professionals and their facilities with the information they need to monitor and improve adherence to the most current, science-based ACC/AHA treatment guidelines. Participation will greatly facilitate quality improvement efforts, optimize clinical care, and improve clinical outcomes for acute coronary syndrome patients.

Visit How To Join to request additional information or to download an enrollment package. Or, visit the ACTION website for more information.



Prognostic value of N-terminal pro-brain natriuretic peptide in elderly people with acute myocardial infarction: prospective observational study



Br Med J 2009: Advance online publication View citation

Objective: To examine the influence of age on the predictive value of N-terminal pro-brain natriuretic (NT-proBNP) peptide assay in acute myocardial infarction.

Design Prospective observational study

Setting All intensive care units in one French region.

Participants 3291 consecutive patients admitted for an acute myocardial infarction, from the RICO survey (a French regional survey for acute myocardial infarction).

Main outcome measure Cardiovascular death at 1 year.

Results Among the 3291 participants, mean age was 68 (SD 14) years and 2356 (72%) were men. In the study population, the median NT-proBNP concentration was 1053 (interquartile range 300-3472) pg/ml. Median values for age quarters 1 to 4 were 367 (119-1050), 696 (201-1950), 1536 (534-4146), and 3774 (1168-9724) pg/ml (P<0.001). A multiple linear regression analysis was done to determine the factors associated with the pro-peptide concentrations in the overall population. NT-proBNP was mainly associated with age, left ventricular ejection fraction, creatinine clearance, female sex, hypertension, diabetes, and anterior wall infarction. At one year’s follow-up, 384 (12%) patients had died from all causes and 372 (11%) from cardiovascular causes. In multivariate analysis, NT-proBNP remained strongly associated with the outcome, beyond traditional risk factors including creatinine clearance and left ventricular ejection fraction, in each age group except in the youngest one (<54 years) (P=0.29). The addition of NT-proBNP significantly improved the performance of the statistical model in the overall study population (–2log likelihood 3179.58 v 3099.74, P<0.001) and in each age quarter including the upper one (1523.52 v 1495.01, P<0.001).The independent discriminative value of NT-proBNP compared with the GRACE score was tested by a diagonal stratification using the median value of the GRACE score and NT-proBNP in older patients (upper quarter). Such stratification strikingly identified a high risk group—patients from the higher NT-proBNP group and with a high risk score—characterised by a risk of death of almost 50% at one year.

Conclusions: In this large contemporary non-selected cohort of patients with myocardial infarction, NT-proBNP concentration had incremental prognostic value even in the oldest patients, above and beyond the GRACE risk score and traditional biomarkers after acute myocardial infarction. These data further support the potential interest of clinical trials specifically assessing NT-proBNP measurement as a guide to current treatment strategies, as well as novel strategies, in older patients with acute myocardial infarction.





Legal information

EMCREG™ - International
4555 Lake Forest Drive
Suite 650
Cincinnati, Ohio 45242

Fell free to contact us toll-free at 1-866-4EMCREG (436-2734)





Advanced Search

2 September 2010
27 August 2010
18 August 2010
9 August 2010
2 August 2010
27 July 2010
19 July 2010
19 July 2010
21 June 2010
18 June 2010
11 June 2010
8 June 2010
8 June 2010
NEWS ARCHIVES:
©Copyright EMCREG-International™. All rights reserved